These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 21400652)

  • 1. Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents.
    Kufner S; Massberg S; Dommasch M; Byrne RA; Tiroch K; Ranftl S; Fusaro M; Schömig A; Kastrati A; Mehilli J;
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):161-6. PubMed ID: 21400652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
    Windecker S; Haude M; Neumann FJ; Stangl K; Witzenbichler B; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Piot C; Richardt G; Merkely B; Schneider H; Bilger J; Erne P; Waksman R; Zaugg S; Jüni P; Lefèvre T
    Circ Cardiovasc Interv; 2015 Feb; 8(2):e001441. PubMed ID: 25634905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
    Han Y; Jing Q; Xu B; Yang L; Liu H; Shang X; Jiang T; Li Z; Zhang H; Li H; Qiu J; Liu Y; Li Y; Chen X; Gao R;
    JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
    Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
    Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
    Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
    Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
    JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
    Kufner S; Byrne RA; Valeskini M; Schulz S; Ibrahim T; Hoppmann P; Schneider S; Laugwitz KL; Schunkert H; Kastrati A;
    EuroIntervention; 2016 Mar; 11(12):1372-9. PubMed ID: 25405657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer.
    Byrne RA; Iijima R; Mehilli J; Pinieck S; Bruskina O; Schömig A; Kastrati A
    JACC Cardiovasc Interv; 2009 Apr; 2(4):291-9. PubMed ID: 19463439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study.
    Onuma Y; Tanimoto S; Ruygrok P; Neuzner J; Piek JJ; Seth A; Schofer JJ; Richardt G; Wiemer M; Carrié D; Thuesen L; Dorange C; Miquel-Hebert K; Veldhof S; Serruys PW
    Catheter Cardiovasc Interv; 2010 Nov; 76(5):634-42. PubMed ID: 20690152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
    Xu B; Dou K; Yang Y; Lv S; Wang L; Wang H; Li Z; Wang L; Chen Y; Huo Y; Li W; Kirtane AJ; Gao R
    EuroIntervention; 2012 Nov; 8(7):796-802. PubMed ID: 23171800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and long-term outcomes of ostial stentings among bare-metal stents, sirolimus-eluting stents, and paclitaxel-eluting stents.
    Hsieh IC; Hsieh MJ; Chang SH; Wang CY; Lee CH; Lin FC; Chen CC
    Coron Artery Dis; 2013 May; 24(3):224-30. PubMed ID: 23571311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
    Loh JP; Stella PR; Sangiorgi G; Silber S; Stahnke S; von Strandmann RP; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2014 Jan; 15(1):23-8. PubMed ID: 24444473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
    Kufner S; Joner M; Thannheimer A; Hoppmann P; Ibrahim T; Mayer K; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
    Circulation; 2019 Jan; 139(3):325-333. PubMed ID: 30586724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.
    Teeuwen K; Adriaenssens T; Van den Branden BJ; Henriques JP; Van der Schaaf RJ; Koolen JJ; Vermeersch PH; Bosschaert MA; Tijssen JG; Suttorp MJ
    Trials; 2012 Dec; 13():240. PubMed ID: 23241457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.